Katsura Sugawara
Research Subjects
Katsura Sugawara has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Kazutaka Kinugasa
Department of Orthopaedic Sports Medicine, Osaka Rosai Hospital, Sakai, Osaka, Japan
1 shared publication Masashi Kusano
Osaka Nakanoshima Orthopaedic Clinic, Osaka, Japan
1 shared publicationRyohei Uchida
Department of Orthopaedic Sports Medicine, Kansai Rosai Hospital, Hyogo, Japan
1 shared publication- Ryosuke Kuroda
Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
1 shared publication Shinobu Yanada
Japan Tissue Engineering Co, Ltd, Aichi, Japan
1 shared publication- Shunsuke Takeuchi
Japan Tissue Engineering Co, Ltd, Aichi, Japan
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by SAGE Publications in Orthopaedic Journal of Sports Medicine
- Vol. 14 (7)
Qualitative and Quantitative Evaluation of Loose Bodies as a Novel Cell Source for Autologous Chondrocyte Implantation
Background: Autologous chondrocyte implantation (ACI) has recently produced successful outcomes, but donor site morbidity remains an urgent issue to be resolved. Thus, alternative cell sources are highly desirable to minimize donor site morbidity. Purpose: To qualitatively and quantitatively evaluate the potential of loose bodies as a novel cell source for ACI. Study Design: Controlled laboratory study. Methods: Loose bodies were obtained from 10 patients during arthroscopic surgery. They were evaluated by gross appearance and histology and classified into normal, abnormal, and no-cartilage groups. Then, 3-dimensional (3D)–cultured cartilage was prepared using chondrocytes from the loose bodies, and cell proliferation and glycosaminoglycan production in the 3D-cultured cartilage were compared with those from native cartilage obtained from patients who underwent total knee arthroplasty. Finally, expression of 42 genes by primary chondrocytes from the loose bodies was analyzed by chondrocyte gene spatial mapping analysis (CGSMA) and compared with that of reference chondrocytes to visualize their global properties, including ossification and denaturation. Results: Of 10 loose bodies, 4 were histologically classified into the normal cartilage group, 4 into the abnormal cartilage group, and 2 into the no-cartilage group. The mean cell proliferation rate of 3D-cultured cartilage from the loose bodies in the normal and abnormal cartilage groups was significantly higher than that of the native cartilage ( P = .020), while there was no significant difference in mean glycosaminoglycan production. Scores for the chondrocyte gene spatial mapping analysis showed that the 3D-cultured cartilage produced from 2 loose bodies exhibited gene expression within the reference range of native cartilage. While 2 of the 10 loose bodies (20%) met the predefined criteria across all 3 evaluations, this proportion increased to 50% (2 of 4) when the analysis was restricted to loose bodies classified in the normal cartilage group. Conclusion: A subset of loose bodies demonstrated matrix-producing capacity without ossification or denaturation, supporting their potential as a cell source for ACI. Clinical Relevance: Appropriately selected loose bodies are a potential cell source for ACI while minimizing donor site morbidity.
- 20 July 2026
- Published by SAGE Publications in Orthopaedic Journal of Sports Medicine
- Vol. 14 (7)
Open AccessQualitative and Quantitative Evaluation of Loose Bodies as a Novel Cell Source for Autologous Chondrocyte Implantation
Background: Autologous chondrocyte implantation (ACI) has recently produced successful outcomes, but donor site morbidity remains an urgent issue to be resolved. Thus, alternative cell sources are highly desirable to minimize donor site morbidity. Purpose: To qualitatively and quantitatively evaluate the potential of loose bodies as a novel cell source for ACI. Study Design: Controlled laboratory study. Methods: Loose bodies were obtained from 10 patients during arthroscopic surgery. They were evaluated by gross appearance and histology and classified into normal, abnormal, and no-cartilage groups. Then, 3-dimensional (3D)–cultured cartilage was prepared using chondrocytes from the loose bodies, and cell proliferation and glycosaminoglycan production in the 3D-cultured cartilage were compared with those from native cartilage obtained from patients who underwent total knee arthroplasty. Finally, expression of 42 genes by primary chondrocytes from the loose bodies was analyzed by chondrocyte gene spatial mapping analysis (CGSMA) and compared with that of reference chondrocytes to visualize their global properties, including ossification and denaturation. Results: Of 10 loose bodies, 4 were histologically classified into the normal cartilage group, 4 into the abnormal cartilage group, and 2 into the no-cartilage group. The mean cell proliferation rate of 3D-cultured cartilage from the loose bodies in the normal and abnormal cartilage groups was significantly higher than that of the native cartilage ( P = .020), while there was no significant difference in mean glycosaminoglycan production. Scores for the chondrocyte gene spatial mapping analysis showed that the 3D-cultured cartilage produced from 2 loose bodies exhibited gene expression within the reference range of native cartilage. While 2 of the 10 loose bodies (20%) met the predefined criteria across all 3 evaluations, this proportion increased to 50% (2 of 4) when the analysis was restricted to loose bodies classified in the normal cartilage group. Conclusion: A subset of loose bodies demonstrated matrix-producing capacity without ossification or denaturation, supporting their potential as a cell source for ACI. Clinical Relevance: Appropriately selected loose bodies are a potential cell source for ACI while minimizing donor site morbidity.
- Open Access
- 24 February 2026
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
Collagen‐membrane‐covered matrix‐associated chondrocyte implantation improves safety over periosteum‐covered MACI for large knee cartilage defects: A real‐world data analysis in the registry study
Purpose: This registry study aimed to evaluate the safety and effectiveness of collagen membrane‐covered matrix‐associated autologous chondrocyte implantation (cMACI) versus periosteum‐covered MACI (pMACI) for large knee cartilage defects (Outerbridge III–IV, ≥4 cm²) in the femorotibial and/or patellofemoral joints with a minimum 2‐year follow‐up. Methods: The safety analysis included 662 knees from 645 patients (mean age: 41.6 ± 14.0 years) with trauma (586 knees, 88.5%) or osteochondritis dissecans (76 knees, 11.5%). Mean final defect size after debridement was 6.6 ± 3.6 cm² (range: 4.0–38 cm²), with ≥4 cm² in 101 knees (15.3%) receiving cMACI and 561 (84.7%) receiving pMACI. Adverse events (AEs) were assessed through physical examination, magnetic resonance imaging (MRI) and arthroscopy. AEs rates were compared between cMACI and pMACI. The effectiveness was assessed using the Lysholm Knee Score (LKS) and the Knee Injury and Osteoarthritis Outcome Score (KOOS) at 6, 12 and 24 months postoperatively. A mixed‐effects model for repeated measures was used for comparative analysis. Results: Analyses showed no significant differences in patient characteristics between groups, except for age (older in the cMACI group), sex (predominantly female), disease aetiology (predominantly trauma) and meniscectomy prevalence (lower). cMACI showed reduced rates of graft hypertrophy (1.0% vs. 10.7%, p = 0.0176), delamination (5.9% vs. 14.1%, p = 0.0350), ossification (0% vs. 2.3%, not applicable), contracture (1.0% vs. 8.7%, p = 0.0302) and treatment failure (3% vs. 9%, p = 0.0037). The per‐protocol set assessing effectiveness included 509 knees (cMACI/pMACI: 70/439), with no significant differences in patient characteristics between groups. The results demonstrated similar postoperative improvements in LKS and KOOS in both groups. Conclusion: cMACI showed superior safety compared with pMACI for large cartilage defects, with similarly improved outcomes in approximately 75% of patients. These findings suggest that the collagen membrane may address periosteum‐related AEs and treatment failures in MACI. Level of Evidence: Level II.
- 24 February 2026
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
Open AccessCollagen‐membrane‐covered matrix‐associated chondrocyte implantation improves safety over periosteum‐covered MACI for large knee cartilage defects: A real‐world data analysis in the registry study
Purpose: This registry study aimed to evaluate the safety and effectiveness of collagen membrane‐covered matrix‐associated autologous chondrocyte implantation (cMACI) versus periosteum‐covered MACI (pMACI) for large knee cartilage defects (Outerbridge III–IV, ≥4 cm²) in the femorotibial and/or patellofemoral joints with a minimum 2‐year follow‐up. Methods: The safety analysis included 662 knees from 645 patients (mean age: 41.6 ± 14.0 years) with trauma (586 knees, 88.5%) or osteochondritis dissecans (76 knees, 11.5%). Mean final defect size after debridement was 6.6 ± 3.6 cm² (range: 4.0–38 cm²), with ≥4 cm² in 101 knees (15.3%) receiving cMACI and 561 (84.7%) receiving pMACI. Adverse events (AEs) were assessed through physical examination, magnetic resonance imaging (MRI) and arthroscopy. AEs rates were compared between cMACI and pMACI. The effectiveness was assessed using the Lysholm Knee Score (LKS) and the Knee Injury and Osteoarthritis Outcome Score (KOOS) at 6, 12 and 24 months postoperatively. A mixed‐effects model for repeated measures was used for comparative analysis. Results: Analyses showed no significant differences in patient characteristics between groups, except for age (older in the cMACI group), sex (predominantly female), disease aetiology (predominantly trauma) and meniscectomy prevalence (lower). cMACI showed reduced rates of graft hypertrophy (1.0% vs. 10.7%, p = 0.0176), delamination (5.9% vs. 14.1%, p = 0.0350), ossification (0% vs. 2.3%, not applicable), contracture (1.0% vs. 8.7%, p = 0.0302) and treatment failure (3% vs. 9%, p = 0.0037). The per‐protocol set assessing effectiveness included 509 knees (cMACI/pMACI: 70/439), with no significant differences in patient characteristics between groups. The results demonstrated similar postoperative improvements in LKS and KOOS in both groups. Conclusion: cMACI showed superior safety compared with pMACI for large cartilage defects, with similarly improved outcomes in approximately 75% of patients. These findings suggest that the collagen membrane may address periosteum‐related AEs and treatment failures in MACI. Level of Evidence: Level II.